Cargando…

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions

BACKGROUND: Rivastigmine is the only cholinesterase inhibitor (ChEI) available as transdermal patch. The patch was developed to improve gastrointestinal tolerability and treatment adherence to higher dosages as compared with oral medication. Preferences of patients and caregivers for the patch were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adler, G, Mueller, B, Articus, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237461/ https://www.ncbi.nlm.nih.gov/pubmed/24588972 http://dx.doi.org/10.1111/ijcp.12374

Ejemplares similares

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
por: Seibert, Johannes, et al.
Publicado: (2012)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon(®) Transdermal Patch (Daily)- A Randomized Clinical Trial
por: Schurad, Bjoern, et al.
Publicado: (2022)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
por: dos Santos, Gustavo Alves Andrade, et al.
Publicado: (2011)

An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch
por: Grieco, T., et al.
Publicado: (2011)

The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease
por: Kim, Hyeyun, et al.
Publicado: (2016)

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice
por: López-Pousa, Secundino, et al.
Publicado: (2013)

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review
por: Kurz, A, et al.
Publicado: (2009)

Neuropsychiatric Symptoms of Alzheimer's Disease and Caregiver Burden
por: Iravani, Behnam, et al.
Publicado: (2022)

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study
por: Tsuno, Norifumi, et al.
Publicado: (2019)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
por: Moretti, Davide V., et al.
Publicado: (2014)

Preparation and Characterization of Rivastigmine Transdermal Patch Based on Chitosan Microparticles
por: Sadeghi, Mohsen, et al.
Publicado: (2016)

A prospective study on the use of rivastigmine transdermal patch in Alzheimer’s dementia in a routine clinical setting
por: Nazir, Ejaz, et al.
Publicado: (2010)

Third degree atrioventricular block associated with treatment with rivastigmine transdermal patch
por: Knudtzen, Fredrikke C., et al.
Publicado: (2013)

Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease
por: Ismail, Manal Fouad, et al.
Publicado: (2013)

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
por: Han, Hyun Jeong, et al.
Publicado: (2011)

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study
por: Muñoz-Moreno, Jose A., et al.
Publicado: (2017)

Polymeric Microneedles for Transdermal Delivery of Rivastigmine: Design and Application in Skin Mimetic Model
por: Guimarães, Tânia M. T., et al.
Publicado: (2022)

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
por: Vagenas, Vassileios, et al.
Publicado: (2015)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
por: Yatawara, Chathuri, et al.
Publicado: (2021)

Development and Validation of a Spectrofluorimetric Method for the Estimation of Rivastigmine in Formulations
por: Kapil, R., et al.
Publicado: (2009)

Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer’s disease
por: Rompicherla, Sampath Kumar L., et al.
Publicado: (2021)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

Assessment of the Burden of Multiple Sclerosis Patients' Caregivers in Saudi Arabia
por: Algahtani, Hussein, et al.
Publicado: (2020)

The Characteristics of Patients Associated With High Caregiver Burden in Parkinson's Disease in Singapore
por: Tan, Mark M. J., et al.
Publicado: (2019)

Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time
por: Riedel, O., et al.
Publicado: (2012)

Caregiver burden and associated factors among primary caregivers of patients with ALS in home care: a cross-sectional survey study
por: Tang, Shan, et al.
Publicado: (2021)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication
por: Straka, Igor, et al.
Publicado: (2019)

Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
por: Shimura, Hideki, et al.
Publicado: (2021)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Rivastigmine-Loaded L-Lactide-Depsipeptide Polymeric Nanoparticles: Decisive Formulation Variable Optimization
por: Pagar, Kunal, et al.
Publicado: (2013)

Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin(®) LA) in school children under daily practice conditions
por: Haertling, Fabian, et al.
Publicado: (2014)

Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer’s disease
por: Kano, Osamu, et al.
Publicado: (2013)

Correction: Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer’s Disease
por: Lefèvre, Gilbert, et al.
Publicado: (2016)

Formulation and Evaluation of Transdermal Patch of Repaglinide
por: Prajapati, Shailesh T., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_516bp6nrtj8907u1ppb4psakia